ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital Market Post author:admERY Post published:April 19, 2023 Post category:Newsroom You Might Also Like ERYTECH announces enrollment of first patient in Phase I/II study of eryaspase in Acute Lymphoblastic Leukemia in the United States July 22, 2014 ERYTECH business update and financial results for the first half of 2013 August 28, 2013 ERYTECH wins Deloitte Technology Fast 50 “Promising Biotech Award” for France’s Grand Rhone-Alpes Region November 18, 2015
ERYTECH announces enrollment of first patient in Phase I/II study of eryaspase in Acute Lymphoblastic Leukemia in the United States July 22, 2014
ERYTECH wins Deloitte Technology Fast 50 “Promising Biotech Award” for France’s Grand Rhone-Alpes Region November 18, 2015
